natgillin/translations-raw huggingface dataset:
In rat and dog repeat-dose toxicity studies up to 6 months duration, target organs for toxicity were GI tract, bone marrow, lymphoid tissues, kidney, adrenal and reproductive tract tissues. 
Ispitivanja toksičnosti ponavljajućih doza u štakora i pasa u trajanju do 6 mjeseci, ciljni organi za toksičnost su bili gastrointestinalni trakt, koštana srž, limfatično tkivo, bubreg te nadbubrežno tkivo i tkivo reproduktivnog trakta.
All three subgroups showed increased PFS in the cabozantinib arm compared to the placebo arm (HRs of 0.23, 0.53, and 0.30 for RET mutation positive, negative, and unknown subgroups, respectively). 
Sve tri podskupine su pokazale povećan PFS u kabozantinib skupini u usporedbi s placebo skupinom (HR od 0,23; 0,53 i 0,30 za skupine pozitivne na mutaciju RET-a, odnosno negativne, odnosno nepoznate).
Juvenile rats (comparable to a >2 year old pediatric population) administered cabozantinib showed increased WBC parameters, decreased haematopoiesis, pubescent/immature female reproductive system (without delayed vaginal opening), tooth abnormalities, reduced bone mineral content and density, liver pigmentation and bile duct hyperplasia. 
U mladih štakora (koji su usporedivi s pedijatrijskom populacijom starosti >2 godine) u kojih je primijenjen kabozantinib došlo je do povećanja parametara leukocita, smanjenja hematopoeze, pubescentnog/nezrelog ženskog spolnog sustava (bez odgođenog vaginalnog otvaranja), abnormalnosti zuba, smanjenog mineralnog sadržaja i gustoće kostiju, pigmentacije jetre i hiperplazije žučovoda.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Ipsen Pharma 
11. NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Ipsen Pharma
Cabozantinib exhibited dose-related tumour growth inhibition, tumor regression, and/or inhibited metastasis in a broad range of preclinical tumour models. 
Kabozantinib je pokazao inhibiciju rasta tumora ovisnu o dozi, utjecao na regresiju tumora i/ili inhibirao metastaze u širokom spektru prekliničkih modela tumora.
Repeat daily dosing of cabozantinib at 140 mg for 19 days resulted in an approximately a 4- to 5-fold mean cabozantinib accumulation (based on AUC) compared to a single dose administration; steady state is achieved by approximately Day 15. 
Ponavljanje dnevne doze kabozantiniba od 140 mg tijekom 19 dana rezultiralo je otprilike četverostruko do peterostruko većom srednjom vrijednosti akumulacije kabozantiniba (na osnovu AUC) u usporedbi s primjenom jedne doze; stanje dinamičke ravnoteže je postignuto otprilike 15.og dana.
• Protein or blood in the urine, gallstones, painful urination 
• Proteini ili krv u mokraći, žučni kamenci, bolno mokrenje
Clinical data in medullary thyroid cancer 
Klinički podaci u bolesnika s medularnim rakom štitnjače
• Inflammation of the lips and corners of the mouth 
• Upala usnica i rubova usta
Non-GI fistula should be ruled out as appropriate in cases of onset of mucositis after start of therapy. 
Fistule izvan gastrointestinalnog sustava se moraju isključiti u slučaju pojave mukozitisa nakon početka terapije.
An oral examination should be performed prior to initiation of cabozantinib and periodically during cabozantinib therapy. 
Prije početka primjene kabozantiniba mora se napraviti oralni pregled te potom periodično tijekom terapije kabozantinibom.
Therefore chronic administration of agents that are strong CYP3A4 inducers with cabozantinib should be avoided (see sections 4.2 and 4.5). 
Prema tome, mora se izbjegavati kroničnu primjenu lijekova koji spadaju u jake induktore CYP3A4 s kabozantinibom (vidjeti dijelove 4.2 i 4.5).
A significant improvement in OS was observed in the subgroup of RET M918T mutation positive patients (n=81/219 cabozantinib arm): 44.3 months in the cabozantinib arm vs. 18.9 months in the placebo arm (HR = 0.60, p = 0.0255). 
Značajno poboljšanje ukupnog preživljenja primijećeno je u podskupini bolesnika koji su bili pozitivni na mutaciju RET M918T (n=81/219 u kabozantinib skupini): 44,3 mjeseca u kabozantinib skupini naspram 18,9 mjeseci u placebo skupini (HR = 0,60, p = 0,0255).
Take the next dose at the normal time. 
Iduću dozu uzmite u predviđeno vrijeme.
Patients with both sporadic and hereditary forms of MTC will be eligible for the study. 
Bolesnici koji imaju i sporadični i nasljedni oblik medularnog karcinoma štitnjače će biti podobni za ispitivanje.
Patients who have evidence of involvement of the trachea or bronchi by tumour or a history of haemoptysis prior to treatment initiation should be carefully evaluated before initiating cabozantinib therapy. 
U bolesnika u kojih postoji dokaz o tumoru koji obuhvaća dušnik ili bronhe ili koji imaju anamnezu hemoptize mora se napraviti pažljiva procjena prije početka liječenja kabozantinibom.
A high-fat meal moderately increased Cmax and AUC values (41% and 57%, respectively) relative to fasted conditions in healthy volunteers administered a single 140 mg oral cabozantinib dose. 
Obrok s visokom količinom masti je umjereno povećao Cmax i AUC vrijednosti (41%, odnosno 57%) u odnosu na stanje natašte u zdravih dobrovoljaca kad se primjenjuje jedna peroralna doza kabozantiniba od 140 mg.
aspergilloma 
aspergilom
Efficacy with cabozantinib was observed in medullary thyroid cancer patients with wild-type or mutant RET. 
Djelotvornost kabozantiniba je zabilježena u bolesnika koji boluju od medularnog raka štitnjače s RET-om divljeg tipa ili mutiranim.
• Fatigue, weakness, headache, dizziness 
• Umor, slabost, glavobolja, omaglica
The result of the PFS analysis, based on the central review RECIST assessment, demonstrated a statistically significant difference in the duration of PFS with cabozantinib versus placebo: the median duration was 11.2 months for subjects in the cabozantinib arm versus 4.0 months for subjects in the placebo arm (stratified Hazard Ratio [HR] = 0.28; 95% CI: 0.19, 0.40; p<0.0001; Figure 1). 
Rezultati PFS analize, temeljeni na centralnoj procjeni RECIST-a, su pokazali statistički značajnu razliku u trajanju PFS-a s kabozantinibom naspram placeba: medijan je bio 11,2 mjeseca u skupini ispitanika kod kojih je primjenjivan kabozantinib nasuprot 4,0 mjeseca u skupini ispitanika kod kojih je primjenjivan placebo (stratificirani omjer rizika [HR] = 0,28; 95% CI: 0,19, 0,40; p<0,0001; Slika 1).
Ear and labyrinth disorders ear pain, tinnitus hypoacusis 
Poremećaji uha i labirinta bol u uhu, tinitus hipoakuzija
Concomitant treatment with strong CYP3A4 inhibitors, which may increase cabozantinib plasma concentrations, should be used with caution. 
Istodobno liječenje lijekovima koji spadaju u skupinu jakih inhibitora CYP3A4, koji mogu povećati koncentracije kabozantiniba u plazmi, mora se primjenjivati s oprezom.
• Infection and inflammation in the lung, collapse of lung 
• Infekcija i upala pluća, kolaps pluća
Cabozantinib treatment should be discontinued in patients with RPLS. 
Mora se prekinuti liječenje s kabozantinibom u bolesnika s RPLS-om.
The most common laboratory abnormalities were increased aspartate aminotransferase (AST), increased alanine aminotransferase (ALT), increased alkaline phosphatase (ALP), lymphopenia, hypocalcaemia, neutropenia, thrombocytopenia, hypophosphataemia, hyperbilirubinemia, hypomagnesaemia, and hypokalaemia. 
Najčešći laboratorijski poremećaji bili su povećanje aspartat aminotransferaze (AST), povećanje alanin aminotransferaze (ALT), povećanje alkalne fosfataze (ALP), limfopenija, hipokalcemija, neutropenija, trombocitopenija, hipofosfatemija, hiperbilirubinemija, hipomagnezemija i hipokalemija.
There are no studies in pregnant women using cabozantinib. 
Nisu provedena ispitivanja s primjenom kabozantiniba u trudnica.
Metabolism and nutrition disorders decreased appetite, hypocalcaemia, hypophosphataemia, hyperbilirubinemia, hypokalaemia, hypomagnesaemia dehydration, hypoalbuminaemia 
Poremećaji metabolizma i prehrane smanjen apetit, hipokalcemija, hipofosfatemija, hiperbilirubinemija, hipokalemija, hipomagnezemija dehidracija, hipoalbuminemija
In patients with mild or moderate hepatic impairment the recommended dose of cabozantinib is 60 mg once daily. 
Preporučena doza kabozantiniba u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre iznosi 60 mg jedanput dnevno.
COMETRIQ 80 mg capsules are orange and have “XL184 80mg” printed on one side. 
COMETRIQ kapsule od 80 mg su narančaste boje i imaju oznaku “XL184 80mg” utisnutu s jedne strane.
• Tear or hole or bleeding in your stomach or intestine, inflammation or tear of anus, , bleeding in lungs or trachea (airway) 
• Razdor, rupa ili krvarenje u želucu ili crijevima, upala ili razdor anusa, krvarenje u plućima ili dušniku (dišnim putovima)
Caution is required when administering cabozantinib with agents that are strong CYP3A4 inhibitors. 
Potreban je oprez prilikom primjene kabozantiniba s lijekovima koji spadaju u jake inhibitore CYP3A4.
Patients who have had recent radiotherapy, have inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, peritonitis, or diverticulitis), have tumour infiltration of trachea, bronchi, or oesophagus, have complications from prior GI surgery (particularly when associated with delayed or incomplete healing), or have complications from prior radiation therapy to the thoracic cavity (including mediastinum) should be carefully evaluated before initiating cabozantinib therapy and subsequently they should be monitored closely for symptoms of perforations and fistulas. 
U bolesnika koji su u skorije vrijeme bili podvrgnuti radioterapiji, imaju upalnu bolest crijeva (npr. Crohnovu bolest, ulcerozni kolitis, peritonitis ili divertikulitis), imaju infiltraciju dušnika, bronha ili jednjaka tumorom, koji su pretrpjeli komplikacije od prethodne gastrointestinalne operacije (naročito komplikacije koje su povezane s usporenim ili nepotpunim cijeljenjem) ili imaju komplikacije od prethodne radioterapije prsnog koša (uključujući medijastinum) mora se napraviti pažljiva procjena prije početka terapije kabozantinibom te slijedom navedenog njih se mora pažljivo pratiti hoće li se pojaviti simptomi perforacija i fistula.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS), also known as Posterior Reversible Encephalopathy Syndrome (PRES) has been observed with cabozantinib. 
Sindrom reverzibilne posteriorne leukoencefalopatije Prilikom primjene kabozantiniba zabilježen je sindrom reverzibilne posteriorne leukoencefalopatije (RPLS), također poznat kao sindrom posteriorne reverzibilne encefalopatije (PRES).
Events that generally have early onset include hypocalcaemia, hypokalaemia, thrombocytopenia, hypertension, palmarplantar erythrodysaesthesia syndrome (PPES), and gastrointestinal (GI) events (abdominal or mouth pain, mucosal inflammation, constipation, diarrhoea, vomiting). 
Događaji koji se većinom javljaju rano uključuju hipokalcemiju, hipokalemiju, trombocitopeniju, hipertenziju, sindrom palmarno-plantarne eritrodizestezije (PPES) i gastrointestinalne (GI) događaje (bol u abdomenu ili ustima, upala sluznice, konstipacija, proljev, povraćanje).
The most frequent adverse reactions of any grade (experienced by at least 20% of patients) included diarrhoea, PPES, weight decreased, decreased appetite, nausea, fatigue, dysgeusia, hair colour changes, hypertension, stomatitis, constipation, vomiting, mucosal inflammation, asthenia, and dysphonia. 
Najčešće nuspojave bilo kojeg stupnja (nuspojave koje su se javile u najmanje 20% bolesnika) uključuju proljev, PPES, gubitak na tjelesnoj težini, smanjen apetit, mučninu, umor, disgeuziju, promjenu boje kose, hipertenziju, stomatitis, konstipaciju, povraćanje, upalu sluznice, asteniju i disfoniju.
Results from a study in patients with hepatic impairment indicate that exposure (AUC0-inf) increased by 81% and 63% in subjects with mild and moderate hepatic impairment, respectively (90% CI for AUC0-inf: 121.44% to 270.34% for mild and 107.37% to 246.67% for moderate). 
Rezultati ispitivanja kod bolesnika s oštećenom funkcijom jetre ukazuju na to da se izloženost (AUC0-inf) povećala za 81 % i 63 % u ispitanika s blagim, odnosno umjerenim oštećenjem funkcije jetre (90% CI za AUC0-inf: 121,44 % do 270,34 % za blago i 107,37 % do 246,67 % za umjereno oštećenje).
In rabbits, cabozantinib produced foetal soft tissue changes (reduced spleen size, small or missing intermediate lung lobe) and increased foetal incidence of total malformations. 
U kunića je kabozantinib uzrokovao promjene u mekom tkivu fetusa (smanjena veličina slezene, smanjenje ili gubitak srednjeg plućnog krila) te povećanu incidenciju ukupnih deformacija u fetusa.
• Generalised pain, chest or muscle pain, ear pain, ringing in ears 
• Opća bol, bol u prsima ili mišićima, bol u uhu, zvonjenje u ušima
Cabozantinib was evaluated for its inhibitory activity against a variety of kinases and was identified as an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor) receptors. 
Ispitivano je inhibitorsko djelovanje kabozantiniba na razne kinaze te se ustanovilo da je kabozantinib inhibitor MET (receptor faktora rasta hepatocita) i VEGF (krvožilni endotelni faktor rasta) receptora.
Concomitant medicinal products that are strong inhibitors of CYP3A4 should be used with caution, and chronic use of concomitant medicinal products that are strong inducers of CYP3A4 should be avoided (see sections 4.4 and 4.5). 
Lijekove koji se uzimaju istodobno, a spadaju u skupinu jakih inhibitora CYP3A4 mora se koristiti s oprezom, a kroničnu primjenu lijekova koji se uzimaju istodobno, a spadaju u skupinu jakih induktora CYP3A4 mora se izbjegavati (vidjeti dijelove 4.4 i 4.5).
Subjects should be cautioned regarding taking a P-gp substrate (e.g., fexofenadine, aliskiren, ambrisentan, dabigatran etexilate, digoxin, colchicine, maraviroc, posaconazole, ranolazine, saxagliptin, sitagliptin, talinolol, tolvaptan) while receiving cabozantinib. 
Ispitanike se mora upozoriti na primjenu supstrata P-gp-a (npr. feksofenadin, aliskiren, ambrisentan, dabigatran eteksilat, digoksin, kolhicin, maravirok, posakonazol, ranolazin, saksagliptin, sitagliptin, talinolol, tolvaptan) za vrijeme primjene kabozantiniba.
Infections and infestations abscess (including visceral, skin, tooth), pneumonia, folliculitis, fungal infection (including skin, oral, genital) 
Infekcije i infestacije apscesi (uključujući apscese visceralnih organa, kože, zuba), pneumonija, folikulitis, gljivične infekcije (uključujući kožne, oralne, genitalne)
• Reduced thyroid activity; symptoms can include: tiredness, weight gain, constipation, feeling cold and dry skin 
• Oslabljen rad štitnjače; simptomi mogu uključivati: umor, dobitak na težini, zatvor, osjećaj hladnoće te suhu kožu
Patients with severe hepatic impairment have not been studied. 
Bolesnici s teškim oštećenjem funkcije bubrega nisu ispitivani.
4.0 months HR: 0.28 (0.19, 0.40) p <0.0001 
4,0 mjeseci HR: 0,28 (0,19; 0,40) p < 0,0001
Nervous system disorders dysgeusia, headache, dizziness cerebrovascular accident, peripheral neuropathy, paraesthesia, ageusia, tremor ataxia, disturbance in attention, hepatic encephalopathy, loss of consciousness, speech disorder, posterior reversible encephalopathy syndrome 
Poremećaji živčanog sustava disgeuzija, glavobolja, omaglica cerebrovaskularni inzult, periferna neuropatija, parestezija, ageuzija, tremor ataksija, poremećaj pažnje, hepatalna encefalopatija, gubitak svijesti, poremećaj govora, sindrom posteriorne reverzibilne encefalopatije
Results from a study in patients with renal impairment indicate that the ratios of geometric LS mean for plasma cabozantinib, Cmax and AUC0-inf were 19% and 30% higher, for subjects with mild renal impairment (90% CI for Cmax 91.60% to 155.51%; AUC0-inf 98.79% to 171.26%) and 2% and 6-7% higher (90% CI for Cmax 78.64% to 133.52%; AUC0-inf 79.61% to 140.11%), for subjects with moderate renal impairment, compared to subjects with normal renal function. 
Rezultati ispitivanja kod bolesnika s oštećenom funkcijom bubrega ukazuju na to da su omjeri geometrijskih srednjih vrijednosti dobivenih metodom najmanjih kvadrata za kabozantinib u plazmi, Cmax i AUC0-inf bili 19 % i 30 % viši, za ispitanike s blagim oštećenjem funkcije bubrega (90% CI za Cmax 91,60 % do 155,51 %; AUC0-inf 98,79 % do 171,26 %) te 2 % i 6-7 % viši (90% CI za Cmax 78,64 % do 133,52 %; AUC0-inf 79,61 % do 140,11 %), za ispitanike s umjerenim oštećenjem funkcije bubrega u usporedbi s ispitanicima s normalnom funkcijom bubrega.
When dose reduction is necessary, it is recommended to reduce to 100 mg daily, 
Kada je smanjenje doze neophodno, preporučuje se smanjiti dozu na
Therefore, concomitant use of MRP2 inhibitors (e.g. cyclosporine, efavirenz, emtricitabine) should be approached with caution. 
Stoga je neophodan oprez prilikom istodobne primjene inhibitora MRP2 (npr. ciklosporina, efavirenza, emtricitabina).
Investigations weight decreased, serum ALT, AST, and ALP increased, blood LDH increased, blood TSH increased, lymphopenia, neutropenia, thrombocytopenia blood creatinine phosphokinase increased activated partial thromboplastin time shortened, eosinophil count increased, platelet count increased 
Pretrage smanjenje težine, povišen ALT, AST i ALP u serumu, povišen LDH u krvi, povišen TSH u krvi, limfopenija, neutropenija, trombocitopenija povišena kreatinin fosfokinaza u krvi skraćenje aktiviranog parcijalnog tromboplastinskog vremena, povećanje broja eozinofila, povećanje broja trombocita
Cabozantinib should not be administered to patients with serious haemorrhage or recent haemoptysis. 
Kabozantinib se ne smije primjenjivati u bolesnika s ozbiljnim krvarenjem ili nedavnom hemoptizom.
Figure 1: Kaplan Meier curve of progression free survival 
Slika 1: Kaplan Meierova krivulja preživljenja bez progresije bolesti
Taking COMETRIQ with food 
Uzimanje lijeka COMETRIQ s hranom
• Abscess (collection of pus, with swelling and inflammation) in the abdomen or pelvis area or in your teeth/gums 
• Gnojna upala (nakupina gnoja, s oticanjem i upalom) u trbuhu ili području zdjelice te na zubima/desnima
• Redness, swelling or pain in the mouth or throat, difficulty in speaking, hoarseness 
• Crvenilo, oticanje ili bol u ustima ili grlu, otežan govor, promuklost
The recommended dose of COMETRIQ is 140 mg once daily, taken as one 80 mg orange capsule and three 20 mg grey capsules. 
Preporučena doza lijeka COMETRIQ iznosi 140 mg jedanput dnevno, a uzima se kao jedna narančasta kapsula od 80 mg i tri sive kapsule od 20 mg.
Vascular disorders hypertension hypotension, venous thrombosis, pallor, peripheral coldness arterial thrombosis Aneurysms and artery dissections 
Krvožilni poremećaji hipertenzija hipotenzija, venska tromboza, bljedilo, periferna hladnoća arterijska tromboza aneurizme i disekcije arterije
The most common serious adverse reactions associated with cabozantinib are pneumonia, mucosal inflammation, hypocalcaemia, dysphagia, dehydration, pulmonary embolism, and hypertension. 
Najčešće ozbiljne nuspojave povezane s kabozantinibom su pneumonija, upala sluznice, hipokalcemija, disfagija, dehidracija, plućna embolija i hipertenzija.
Stearic acid 
Sekvestranti žučne kiseline
How to take COMETRIQ 4. 
Kako uzimati COMETRIQ 4. Moguće nuspojave
How to take COMETRIQ 
Kako uzimati COMETRIQ
The ORR was 27.9% and 0% for subjects in the cabozantinib arm and placebo arm, respectively (p<0.0001; Table 2). 
ORR je iznosio 27,9% za skupinu ispitanika u kojih je primjenjivan kabozantinib i 0% za skupinu ispitanika u kojih je primjenjivan placebo (p< 0,0001; Tablica 2).
When dose reduction is necessary, it is recommended to reduce to 100 mg daily, taken as one 80 mg orange capsule and one 20 mg grey capsule, and then to 60 mg daily, taken as three 20 mg grey capsules. 
Kada je smanjenje doze neophodno, preporučuje se smanjiti dozu na 100 mg dnevno, pri čemu se doza uzima kao jedna narančasta kapsula od 80 mg i jedna siva kapsula od 20 mg te zatim smanjiti dozu na 60 mg dnevno, pri čemu se doza uzima kao tri sive kapsule od 20 mg.
Administration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 27 days) to healthy volunteers decreased cabozantinib clearance (by 29%) and increased single-dose plasma cabozantinib exposure (AUC) by 38%. 
Primjenom jakog inhibitora CYP3A4 ketokonazola (400 mg dnevno tijekom 27 dana) u zdravih dobrovoljaca se smanjio klirens kabozantiniba (za 29%) te povećala jednokratna ekspozicija kabozantiniba u plazmi (AUC) za 38%.
Therefore, administration of MRP2 inhibitors may result in increases in cabozantinib plasma concentrations. 
Stoga primjena inhibitora MRP2 može dovesti do povećanja koncentracija kabozantiniba u plazmi.
• Swelling, pain in your hands and feet, or shortness of breath. 
• Oticanje, bol u šakama i stopalima ili nedostatak zraka.
Administration of MRP2 inhibitors may result in increases in cabozantinib plasma concentrations. 
Primjena inhibitora MRP2 može dovesti do povećanja koncentracija kabozantiniba u plazmi.
Ipsen Pharma SAS Lietuvos filialas 
Ipsen Pharma SAS Lietuvos filialas T.
• Symptoms including pain in the abdomen, nausea, vomiting, constipation, or fever. 
• Simptomi kao što su bol u trbuhu, mučnina, povraćanje, zatvor ili vrućica.
No dose adjustment is indicated when gastric pH modifying agents (i.e., PPIs, H2 receptor antagonists, and antacids) are co-administered with cabozantinib. 
Nije potrebno prilagođavanje doze kada se lijekovi koji mijenjaju pH želuca (tj. inhibitori protonske pumpe, antagonisti H2 receptora i antacidi) primjenjuju istodobno s kabozantinibom.
A multi-center, randomized double-blind study comparing cabozantinib (N = 219) with placebo (N = 111) was conducted in patients with unresectable locally advanced or metastatic MTC and documented radiographic disease progression within 14 months prior to study entry. 
(N = 219) s placebom (N = 111) u bolesnika s inoperabilnim lokalno uznapredovalim ili metastatskim medularnim karcinomom štitnjače i dokumentiranom radiografskom progresijom bolesti unutar 14 mjeseci prije početka ispitivanja.
Cabozantinib should be discontinued in patients who develop nephrotic syndrome. 
Mora se prekinuti s primjenom kabozantiniba u bolesnika u kojih se pojavi nefrotski sindrom.
• Inflammation of the oesophagus; symptoms can include heartburn, chest pain, feeling sick, altered taste, bloating, belching and indigestion 
• Upala jednjaka; simptomi mogu uključivati žgaravicu, bol u prsima, mučninu, izmijenjen osjet okusa, nadutost, podrigivanje i probavne tegobe
In case of hypertensive crisis, cabozantinib should be discontinued. 
Ako se javi hipertenzivna kriza, mora se prekinuti s primjenom kabozantiniba.
Cabozantinib treatment should be stopped at least 28 days prior to scheduled surgery, if possible. 
Ako je moguće, mora se prekinuti liječenje kabozantinibom najmanje 28 dana prije zakazane operacije.
• 100 mg (1 orange 80 mg capsule and 1 grey 20 mg capsule) 
• 100 mg (1 narančasta kapsula od 80 mg i 1 siva kapsula od 20 mg)
CYP3A4 inducers and inhibitors 
Inhibitori i induktori CYP3A4
Co-administration of proton pump inhibitor (PPI) esomeprazole (40 mg daily for 6 days) with a single dose of 100 mg cabozantinib to healthy volunteers resulted in no clinically-significant effect on plasma cabozantinib exposure (AUC). 
Istodobna primjena inhibitora protonske pumpe (IPP) esomeprazola (40 mg dnevno tijekom 6 dana) s jednokratnom dozom od 100 mg kabozantiniba u zdravih dobrovoljaca nije imala klinički značajan učinak na izloženost kabozantinibu u plazmi (AUC).
In the event of suspected overdose, cabozantinib should be withheld and supportive care instituted. 
U slučaju sumnje na predoziranje, mora se prestati s primjenom kabozantiniba te uvesti potpornu njegu.
Therefore, cabozantinib may have the potential to increase plasma concentrations of co-administered substrates of P-gp. 
Prema tome, moguće je da kabozantinib može povećati koncentracije u plazmi supstrata P-gp-a koji se primjenjuju istodobno s njim.
• 140 mg (1 orange 80 mg capsule and 3 grey 20 mg capsules) 
• 140 mg (1 narančasta kapsula od 80 mg i 3 sive kapsule od 20 mg)